Target intelligence / Profile preview

SH3PXD2A antisense RNA 1 (SH3PXD2A-AS1)

Target
SH3PXD2A-AS1
Molecular classification
Long non-coding RNA (lncRNA), Other (RNA gene, non-protein coding)
01

Overview

SH3PXD2A antisense RNA 1 (SH3PXD2A-AS1) is a long non-coding RNA transcribed antisense to the SH3PXD2A gene. Located on chromosome 10, SH3PXD2A-AS1 is about 2023 base pairs in length. It is strongly upregulated in various cancers, such as colorectal cancer and non-small cell lung cancer, where it promotes cell cycle progression, proliferation, and tumor growth. Mechanistically, it interacts with protein partners such as DHX9 (to regulate FOXM1 expression) and p53 (to regulate p53 target genes), impacting oncogenic processes and cell fate decisions. In preeclampsia, SH3PXD2A-AS1 inhibits trophoblast invasion by recruiting CTCF to promoters and suppressing gene transcription. While not a classical receptor or enzyme, its emerging roles as an oncogenic lncRNA and disease biomarker make it a candidate for future RNA-based therapies in precision medicine.

Other names
SH3PXD2A-AS1SH3PXD2A antisense RNA 1
02

Mechanism of action

No approved drugs yet; mechanisms include modulation of cell cycle and proliferation via RNA interference or future lncRNA-targeting approaches.

03

Biological functions

Cell cycle regulation (promotes cell cycle progression)Cell proliferationCell migration and invasionTranscriptional regulation (interacts with transcription factors and regulatory proteins)
04

Disease associations

Cancer (colorectal cancer, non-small cell lung cancer, associated with poor prognosis in multiple cancers)Preeclampsia (regulates trophoblast invasion, implicated in pathogenesis)
05

Safety considerations

Potential off-target effects of lncRNA-based therapeuticsUnclear normal physiological role; alteration may disrupt non-pathological cell functionsNo clinical drug safety profile, as lncRNA is not yet directly targeted with approved agents
06

Biomarkers

SH3PXD2A-AS1 expression levels (for prognosis and diagnosis in cancer)Possibly used to stratify patients for therapies targeting lncRNA-driven pathways

Beyond the preview

Go deeper on SH3PXD2A antisense RNA 1 (SH3PXD2A-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SH3PXD2A antisense RNA 1 (SH3PXD2A-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call